Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity

Laquinimod is a novel oral drug that is currently being evaluated for the treatment of relapsing-remitting (RR) multiple sclerosis (MS). Using the animal model for multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), we examined how laquinimod promotes immune modulation. Oral laquini...

Descripción completa

Detalles Bibliográficos
Autores principales: Schulze-Topphoff, Ulf, Shetty, Aparna, Varrin-Doyer, Michel, Molnarfi, Nicolas, Sagan, Sharon A., Sobel, Raymond A., Nelson, Patricia A., Zamvil, Scott S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316495/
https://www.ncbi.nlm.nih.gov/pubmed/22479444
http://dx.doi.org/10.1371/journal.pone.0033797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316495/
https://www.ncbi.nlm.nih.gov/pubmed/22479444
http://dx.doi.org/10.1371/journal.pone.0033797

Ejemplares similares